• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • Insight
11 min read 15th March 2019

HTA in Japan: Failing to Meet International Good Practice?

The Japanese government has recently announced new plans to implement HTA from April 2019. The ISPOR HTA Task Force published ‘Good Practices in HTA’ in January 2019. The Japanese proposals do not meet them. The Japanese Government recently announced plans…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

The Japanese government has recently announced new plans to implement HTA from April 2019. The ISPOR HTA Task Force published ‘Good Practices in HTA’ in January 2019. The Japanese proposals do not meet them.

The Japanese Government recently announced plans for health technology assessment (HTA) to be implemented from April 2019. At a meeting organised by PhRMA, I set out my concerns about the proposals, putting them in the context of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Task Force Report on Good Practices in HTA, published in Value in Health in January 2019.

The proposals follow a pilot project begun by the Central Social Insurance Medical Council (Chuikyo) in April 2016. Japan has a complex drug pricing system which includes criteria under which a drug can get a price premium for its innovative contribution to patients and to the health system. HTA is to be used to retrospectively assess whether the premium element of the price is justified. The premium can be cut by up to 90% depending on the outcome of the HTA assessment. In addition, certain imported products priced by a cost calculation method can have their operating profit margin cut by up to 50%.

We can note that the HTA for drugs is aimed primarily at innovative new medicines notably imported products (although medical devices are also included in the HTA remit). An expected budget impact criterion will be used, and drugs with a high unit price or which are otherwise deemed by the Chuikyo to require cost-effectiveness analysis (CEA) will be included. Products used only for rare diseases with no current treatment, or used only in paediatric diseases will be exempt from HTA.

The ISPOR HTA Task Force report identifies four aspects of HTA process: (i) governance, framing and scoping; (ii) assessment; (iii) contextualisation; and (iv) implementation and monitoring. Assessment in Japan follows a standard methods approach and the premium adjustment to the Japanese price does not have much impact on product use in Japan, so I focus my comments on (i) and (iii).

Governance, framing and scoping

The governance arrangements do not yet follow good practice. The ISPOR Task Force notes the WHO TAPIC (Transparency, Accountability, Participation; Integrity; Capacity) model. The ISPOR HTA Task Force describes “the desired outcome of a good scoping process is dependent on designing one or more clear questions with an assessed feasibility of identifying and interpreting the research that could be utilized to provide answer(s) to the questions posed.” The new process in Japan includes a framing and scoping meeting, but guidelines are needed for this pre-assessment meeting in order to ensure it is effective in achieving an understanding of what evidence is relevant.

Whilst the Methods Guide sets out recognised methods it lacks clarity for companies submitting evidence. A Submission Guide is needed that explains how to submit evidence. It is also not clear from pilots and proposal how evidence will be used and how reanalysis will be sufficiently shared with companies to ensure any errors or misunderstandings are identified and resolved quickly. One confusion, around the non-standard calculation of weighted incremental cost-effectiveness ratios (ICERs) was discussed in Kamae (2018) and a new method proposed.

Contextualisation: from evidence to decisions

The ISPOR HTA Task Force notes that “The complexity of considering different [social] values simultaneously and the need for fairness and consistency has led to more systematic and transparent approaches to incorporating what is considered to key societal decision makers. These include deliberative processes, multi-criteria decision analytic processes, and other forms of contextualising evidence that informs decisions… Specific recent attention has been paid to how to engage patients, who have been traditionally removed from the process of expert consultation.”

However, the proposed Japan HTA process has no opportunity for patient engagement, and uses only a cost per quality-adjusted life year (QALY) threshold rule of JPY5million ($45,000) in decision making based on a 2009 study. If the ICER exceeds this, price premiums are progressively reduced using a stepwise reduction until at JPY10million the maximum reduction of 90% is applied. For drugs with rare disease indications, paediatric indications, or which are anti-cancer agents the threshold range is 50% higher, i.e. JPY7.5million to 90% reduction at JPY15million. Although it was reported that “other outcomes are allowed to be used, depending on the characteristics of the technology” (Shiroiwa et al. 2017) this does not happen in practice. Long term care costs and productivity loss can both be calculated “but should not be included in the base case” and there is no mechanism by which they can be taken into account. 

Two arguments are made against using a broader contextualisation or appraisal process in Japan. The first is that this only affects the industry and not patient access to products. By implication the industry could live with rough justice on its price premiums (and operating profit margins). Leaving aside the potential negative implications for future R&D, one hopes that the methods adopted and the initial use proposed for HTA are only the start and not the end point for how HTA will be used in Japan. In which case, learning how to take a more comprehensive and sophisticated approach would make sense. In other words, if getting it wrong has limited consequences, all the more case for using this as an opportunity to experiment and reflect on the best approaches.

The second argument was that a deliberative process is not acceptable in Japan, and that formulas are needed which do not allow for discretion. Hence the attraction of reliance on a rigid cost-per-QALY threshold formula using only different thresholds for priority categories of products. Yet the ISPOR HTA Task Force notes “an increased focus on the need for HTA processes to be fair” referencing the “accountability for reasonableness” framework. Japan could take the lead in operationalising multi-criteria decision analysis type approaches, scoring relevant attributes that were deemed relevant. PhRMA has proposed such an approach at a Chuikyo hearing which could provide a starting point for dialogue. Indeed the premium price setting approach uses a form of deliberation looking at different elements, leading to a score being given.

In short, Japan’s processes fall short of HTA good practice. This can be remedied, notably by documenting process, and by involving other stakeholders, notably patients. Japan’s particular focus on a formulaic approach to price setting has limitations. It provides it, however, with an opportunity to explore whether forms of structured decision making, based on MCDA, can systematically capture non-QALY attributes and relevant social values and combine them within a QALY-based system. It could lead the world in doing this.

Funding declaration and disclaimer: Adrian Towse’s participation in the PhRMA press conference was funded by PhRMA. The views expressed in this blog are personal and do not represent those of any institution.

References

Health Labor Sciences Research Grant (Research on Policy Planning and Evaluation) Team. Central Social Insurance Medical Council Analysis Guidelines for Cost-Effectiveness Assessment, Version 2 (draft) 12. 27. 2018 version.

Kamae, I. Trial Implementation of Quasi Value-based Pricing for Pharmaceuticals and Medical Devices in Japan: Issues in Dispute. RFAS – 2018 – N° 3: 227-248. Available at: https://www.cairn.info/revue-francaise-des-affaires-sociales-2018-3-page-227.htm

Kristensen et al. (2019). Identifying the Need for Good Practices in Health Technology Assessment: Summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA. Available at: https://www.ispor.org/member-groups/councils-roundtables/health-technology-assessment-council/health-technology-assessment-good-practices-recommendation

Kristensen et al. (2019). Identifying the Need for Good Practices in Health Technology Assessment: Summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA (Online Appendix). Available at https://www.ispor.org/member-groups/councils-roundtables/health-technology-assessment-council/health-technology-assessment-good-practices-recommendation

PhRMA, EFPIA Pitch Enhanced Appraisal Model for Japan HTA Plan; Chuikyo Reps Acknowledge ICER Limitations. December 20, 2018. Available at https://pj.jiho.jp/article/239058

Shiroiwa, T et al. (2017). Development of an Official Guideline for the Economic Evaluation of Drugs/Medical Devices in Japan. Value in Health 20 (2017) 372-378. Available at https://www.sciencedirect.com/science/article/pii/S1098301516313067

  • Health Technology Assessment…
  • Value, Affordability, and…
  • Pricing and Reimbursement

Related Insights

Fishing on the lake at sunset. Fishing background.
  • Insight
  • February 2023

Fishing for Innovative Drugs with the ODRS: Potential Benefits and Challenges

Read more
Cancer_WellcomeCollection_landscape
  • Insight
  • January 2023

Combination Therapies: A Step Forward to the Value Attribution Problem

Read more
G7Antibiotics_blog_featuredimage
  • Insight
  • December 2022

G7 Investments in New Antibiotics Would Pay Off – For Everyone

Read more
Slide3
  • Insight
  • October 2022

The Economics of Antibiotics – Part 3: Creating a Healthy Global Market for New Antibiotics

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!